Is NRXP or AQST more profitable?

Aquestive Therapeutics has a net margin of -144.63% compared to NRx Pharmaceuticals' net margin of -691.81%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Aquestive Therapeutics -144.63% N/A -52.40%

Does the media favor NRXP or AQST?

In the previous week, NRx Pharmaceuticals had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 9 mentions for Aquestive Therapeutics. NRx Pharmaceuticals' average media sentiment score of 0.70 beat Aquestive Therapeutics' score of 0.46 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OCS or NRXP more profitable?

NRx Pharmaceuticals has a net margin of -691.81% compared to Oculis' net margin of -6,777.18%. NRx Pharmaceuticals' return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -6,777.18% -42.61% -35.23% NRx Pharmaceuticals -691.81% N/A -63.92%

Does the media favor OCS or NRXP?

In the previous week, NRx Pharmaceuticals had 4 more articles in the media than Oculis. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 6 mentions for Oculis. NRx Pharmaceuticals' average media sentiment score of 0.70 beat Oculis' score of 0.35 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NRx Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TLRY or NRXP?

In the previous week, Tilray Brands had 7 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 17 mentions for Tilray Brands and 10 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.70 beat Tilray Brands' score of 0.48 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 5 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NRx Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRXP or EOLS more profitable?

Evolus has a net margin of -10.85% compared to NRx Pharmaceuticals' net margin of -691.81%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Evolus -10.85% N/A -13.00%

Does the media refer more to NRXP or EOLS?

In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Evolus. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat NRx Pharmaceuticals' score of 0.70 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OVID or NRXP?

In the previous week, Ovid Therapeutics had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 12 mentions for Ovid Therapeutics and 10 mentions for NRx Pharmaceuticals. Ovid Therapeutics' average media sentiment score of 0.75 beat NRx Pharmaceuticals' score of 0.70 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NRx Pharmaceuticals (NRXP) Competitors

$3.32 -0.07 (-2.06%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.38 +0.06 (+1.81%)

As of 09/18/2026 07:49 PM Eastern

Compare

NRXP vs. AQST, OCS, TLRY, EOLS, and OVID

Should you buy NRx Pharmaceuticals stock or one of its competitors? NRx Pharmaceuticals's main competitors and comparable companies include Aquestive Therapeutics (AQST), Oculis (OCS), Tilray Brands (TLRY), Evolus (EOLS), and Ovid Therapeutics (OVID). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NRx Pharmaceuticals compare to Aquestive Therapeutics?

NRx Pharmaceuticals (NASDAQ:NRXP) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

NRx Pharmaceuticals has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	116.87	-$28.62M	-$0.55	N/A
Aquestive Therapeutics	$44.54M	12.99	-$83.78M	-$0.65	N/A

NRx Pharmaceuticals presently has a consensus target price of $34.50, indicating a potential upside of 939.16%. Aquestive Therapeutics has a consensus target price of $9.17, indicating a potential upside of 98.84%. Given NRx Pharmaceuticals' higher possible upside, research analysts clearly believe NRx Pharmaceuticals is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

NRx Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 9 mentions for Aquestive Therapeutics. NRx Pharmaceuticals' average media sentiment score of 0.70 beat Aquestive Therapeutics' score of 0.46 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aquestive Therapeutics has a net margin of -144.63% compared to NRx Pharmaceuticals' net margin of -691.81%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Summary

NRx Pharmaceuticals and Aquestive Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Oculis?

Oculis (NASDAQ:OCS) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

22.3% of Oculis shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NRx Pharmaceuticals has lower revenue, but higher earnings than Oculis. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	405.46	-$119.44M	-$1.74	N/A
NRx Pharmaceuticals	$1.23M	116.87	-$28.62M	-$0.55	N/A

Oculis currently has a consensus price target of $39.44, indicating a potential upside of 289.00%. NRx Pharmaceuticals has a consensus price target of $34.50, indicating a potential upside of 939.16%. Given NRx Pharmaceuticals' higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

NRx Pharmaceuticals has a net margin of -691.81% compared to Oculis' net margin of -6,777.18%. NRx Pharmaceuticals' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

Oculis has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 4 more articles in the media than Oculis. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 6 mentions for Oculis. NRx Pharmaceuticals' average media sentiment score of 0.70 beat Oculis' score of 0.35 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NRx Pharmaceuticals beats Oculis on 9 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

NRx Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45M	0.59	-$121.40M	-$1.08	N/A
NRx Pharmaceuticals	$1.23M	116.87	-$28.62M	-$0.55	N/A

Tilray Brands currently has a consensus target price of $8.00, suggesting a potential upside of 100.50%. NRx Pharmaceuticals has a consensus target price of $34.50, suggesting a potential upside of 939.16%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Tilray Brands has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

Tilray Brands has a net margin of -13.11% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Tilray Brands had 7 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 17 mentions for Tilray Brands and 10 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.70 beat Tilray Brands' score of 0.48 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	5 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NRx Pharmaceuticals beats Tilray Brands on 9 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Evolus?

NRx Pharmaceuticals (NASDAQ:NRXP) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

NRx Pharmaceuticals has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	116.87	-$28.62M	-$0.55	N/A
Evolus	$297.18M	1.75	-$51.64M	-$0.52	N/A

Evolus has a net margin of -10.85% compared to NRx Pharmaceuticals' net margin of -691.81%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Evolus	-10.85%	N/A	-13.00%

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Evolus has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Evolus. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat NRx Pharmaceuticals' score of 0.70 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NRx Pharmaceuticals presently has a consensus price target of $34.50, indicating a potential upside of 939.16%. Evolus has a consensus price target of $14.50, indicating a potential upside of 84.48%. Given NRx Pharmaceuticals' higher possible upside, equities analysts plainly believe NRx Pharmaceuticals is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

NRx Pharmaceuticals beats Evolus on 8 of the 15 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Ovid Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

In the previous week, Ovid Therapeutics had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 12 mentions for Ovid Therapeutics and 10 mentions for NRx Pharmaceuticals. Ovid Therapeutics' average media sentiment score of 0.75 beat NRx Pharmaceuticals' score of 0.70 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 123.05%. NRx Pharmaceuticals has a consensus price target of $34.50, indicating a potential upside of 939.16%. Given NRx Pharmaceuticals' higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Ovid Therapeutics has higher revenue and earnings than NRx Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	72.46	-$17.41M	-$0.31	N/A
NRx Pharmaceuticals	$1.23M	116.87	-$28.62M	-$0.55	N/A

Ovid Therapeutics has a net margin of -240.11% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-23.64%	-20.52%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Ovid Therapeutics beats NRx Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get NRx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXP vs. The Competition

Export

Metric	NRx Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$143.74M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-6.04	792.21	274.93	25.38
Price / Sales	116.87	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	-6.15	10.53	10.46	6.33
Net Income	-$28.62M	$2.82B	$3.49B	$358.33M
7 Day Performance	-2.35%	1.69%	0.59%	1.12%
1 Month Performance	-0.30%	0.83%	-2.01%	-2.67%
1 Year Performance	11.78%	3.90%	18.09%	6.01%

NRx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXP NRx Pharmaceuticals	1.9621 of 5 stars	$3.32 -2.1%	$34.50 +939.2%	+11.4%	$143.74M	$1.23M	N/A	29
AQST Aquestive Therapeutics	2.5649 of 5 stars	$4.56 -2.3%	$9.17 +101.2%	-6.7%	$570.44M	$44.54M	N/A	147	News Coverage Insider Trade
OCS Oculis	2.2917 of 5 stars	$9.75 -2.3%	$39.44 +304.6%	-41.7%	$565.25M	$1.45M	N/A	60	News Coverage Analyst Forecast
TLRY Tilray Brands	3.8446 of 5 stars	$3.94 -0.1%	$8.00 +103.3%	-68.3%	$535.95M	$915.45M	N/A	3,595
EOLS Evolus	3.0692 of 5 stars	$7.94 -0.9%	$14.50 +82.6%	+22.4%	$524.17M	$297.18M	N/A	353	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXP) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. AQST, OCS, TLRY, EOLS, and OVID

How does NRx Pharmaceuticals compare to Aquestive Therapeutics?

Summary

How does NRx Pharmaceuticals compare to Oculis?

Summary

How does NRx Pharmaceuticals compare to Tilray Brands?

Summary

How does NRx Pharmaceuticals compare to Evolus?

Summary

How does NRx Pharmaceuticals compare to Ovid Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. AQST, OCS, TLRY, EOLS, and OVID

How does NRx Pharmaceuticals compare to Aquestive Therapeutics?

Which has higher earnings and valuation, NRXP or AQST?

Do analysts prefer NRXP or AQST?

Which has more volatility and risk, NRXP or AQST?

Does the media favor NRXP or AQST?

Do institutionals & insiders have more ownership in NRXP or AQST?

Is NRXP or AQST more profitable?

Summary

How does NRx Pharmaceuticals compare to Oculis?

Do institutionals and insiders believe in OCS or NRXP?

Which has stronger earnings and valuation, OCS or NRXP?

Do analysts rate OCS or NRXP?

Is OCS or NRXP more profitable?

Which has more volatility & risk, OCS or NRXP?

Does the media favor OCS or NRXP?

Summary

How does NRx Pharmaceuticals compare to Tilray Brands?

Which has higher valuation and earnings, TLRY or NRXP?

Do analysts prefer TLRY or NRXP?

Which has more volatility & risk, TLRY or NRXP?

Is TLRY or NRXP more profitable?

Do insiders & institutionals hold more shares of TLRY or NRXP?

Does the media prefer TLRY or NRXP?

Summary

How does NRx Pharmaceuticals compare to Evolus?

Which has preferable valuation and earnings, NRXP or EOLS?

Is NRXP or EOLS more profitable?

Do insiders & institutionals believe in NRXP or EOLS?

Which has more volatility & risk, NRXP or EOLS?

Does the media refer more to NRXP or EOLS?

Do analysts prefer NRXP or EOLS?

Summary

How does NRx Pharmaceuticals compare to Ovid Therapeutics?

Which has more risk & volatility, OVID or NRXP?

Does the media refer more to OVID or NRXP?

Do analysts rate OVID or NRXP?

Which has higher valuation & earnings, OVID or NRXP?

Is OVID or NRXP more profitable?

Do institutionals & insiders believe in OVID or NRXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools